Pharma Nord - Research and Manufacturing

Research and Manufacturing

Pharma Nord's products, both medical drugs and dietary supplements, are manufactured in accordance with the current Good Manufacturing Practice (GMP) and Hazard Analysis and Critical Control Points (HACCP) guidelines. The production of medical drugs is regulated by GMP, and dietary supplements are regulated by HACCP. Pharma Nord applies the strictest rules from either regulation in all aspects of production.

Pharma Nord's selenium dietary supplement SelenoPrecise is currently used in the Prevention of Cancer by Intervention with Selenium (PRECISE) study, a population study involving 40,000 test participants from Denmark, Sweden and England.

Pharma Nord's coenzyme Q10 preparation is a reference product for the International Coenzyme Q10 Association. Pharma Nord also actively supports scientific research into the health benefits of coenzyme Q10, and has launched Q-symbio, a large multinational study, investigating coenzyme Q10's potential as an adjuvant for treating chronic heart failure. The remarkable, preliminary results are, that Coenzyme Q10 decreased all cause mortality by half. This was presented by lead author Professor Svend Aage Mortensen at the congress Heart Failure 2013 held from 25-28 May in Lisbon, Portugal. The Q-symbio study randomised 420 patients with severe heart failure (New York Heart Association (NYHA) Class III or IV) to CoQ10 or placebo and followed them for 2 years. The product used in the Q-symbio study was Pharma Nord's 100 mg Q10 in soft-gel capsules (Myoqinon).